

SUPER SPECIALITY PEDIATRIC HOSPITAL AND POST-GRADUATE TEACHING INSTITUTE, SECTOR 30, NOIDA. 201303

# Form to be filled by the Principal Investigator (PI) for submission

(For attachment to each copy of the proposal)

Serial No (IEC Office)

1. <u>Proposal Title</u> (in capi	ital letters)			
2. <u>Proposal for</u> PG	PhD INTRAM	MURAL	EXTRAMURAL	
3. Status	NEW / I	REVISED	(Strike out which is not a	pplicable)
4. Principal Investigator	(in capital letters)(F	or PG/PhD Dis	ssertations – the student sh	ould be the PI)
Designation of PI				
Correspondence Address				
Email ID				
5. Details of other Invest	tigators/Supervisors			
Name (Indicate Supervisor/Chief Supervisor in case of thesis)	Designation Qualifications		spondence Address lephone Number Email ID	Signature



SUPER SPECIALITY PEDIATRIC HOSPITAL AND POST-GRADUATE TEACHING INSTITUTE, SECTOR 30, NOIDA. 201303

# 6. Sponsor Information

(Tick appropriatelyWrite NA if not applicable)

Does the stu	dy involve an Indian Sp	onsor?	Yes/No	
If ye	es, please indicate if the	sponsor is		
	Government	Central/State	Details _	
	Private			
	Institutional			
Does the stu	dy involve an internatio	nal sponsor	Yes/No	
If ye	es please provide details			
Is this a stud	ly sponsored by pharma	ceutical industry?	Yes/no	
If ye	es,		National	/ Multinational
Plea	se give details,			
Total Budge	t for the study		Rupees	
7. <u>Type of s</u>	study(Tick appropria	tely or write NA i	fnot applicable)	
Type	Animal Stu	dy	Human	Basic Sciences
Centers	Single cente	er	Multi-center	
Type of stud	dy			
	arintiva			
Desc	cripuve			
Desc	Cross Sectional Sur	vey Qualitative Re	search	
	•	vey Qualitative Re	search	
	Cross Sectional Sur		search sectional / Cohort	/ Case Control)



SUPER SPECIALITY PEDIATRIC HOSPITAL AND POST-GRADUATE TEACHING INSTITUTE, SECTOR 30, NOIDA. 201303

# 8. Clinical Trials

Drug /Vaccines/Device/Herbal Remedies :						
Does the study involve use of:						
Drug Devices Vaccin	es					
Indian Systems of Medicine/ Any other NA						
Alternate System of Medicine						
Is it approved and marketed						
In India UK & Europe USA						
Other countries, specify		_				
Does it involves change in use, dosage, route of administration?	Yes	No				
If yes, whether DCGI's /Any other Regulatory authority's	1 03	110				
Permission is obtained?	Yes	No				
If yes, Date of permission:		2.0				
Is it an Investigational New Drug?	Yes	No				
If yes, IND No:	37	NI				
a) Investigator's Brochure submitted	Yes	No				
b) In vitro studies data	Yes	No				
c) Preclinical Studies done	Yes	No				
d) Clinical Study is: Phase I Phase II Phase III Phase I	V 🗌					
e) Are you aware if this study/similar study is being done elswhere?	Yes	No				
If Yes, attach details						

# 9. Brief description of the proposal

Introduction, review of literature, aim(s) & objectives, justification for study, methodology describing the potential risks & benefits, outcome measures, statistical analysis and whether it is of national significance with rationale (Attach sheet with maximum 500 words)



SUPER SPECIALITY PEDIATRIC HOSPITAL AND POST-GRADUATE TEACHING INSTITUTE, SECTOR 30, NOIDA. 201303

### 10. Subject Selection

(Tick appropriately or write NA if not applicable)

- a) Number of subjects b) Duration of study c) Will the subjects from both genders be recruited for the study Yes / No a. If not please give details and reasons d) Inclusion / Exclusion criteria have been described Yes / No Patients / Healthy Volunteers / Relatives / Students / Animals e) Type of subjects Are any of the following groups involved in the study Mentally challenged a. Pregnant Women Children Terminally ill Elderly Critically ill
- g) Does your research involve special groups
  - a. Captives or inmates of correctional facilities

Differently abled

- b. Institutionalized inmates
- c. Employees of the institution

- d. Students
- e. Nurses
- f. Dependent staff

Economically and socially

backward groups

g. Armed forces

### 11. Privacy and confidentiality

d. Fetus

Illiterate

(Tick appropriately or write NA if not applicable)

- a) Does your study involve
  - a. Direct Identifiers
    b. Indirect identifiers (coding)
    c. Completely anonymized or delinked data
    Yes / No
- b) Does your study ensure confidential data handling by staff

  Yes / No
- c) Does your study involve transfer/sharing of data to other investigators outside your institution? If yes, please explain methods to ensure confidentiality



SUPER SPECIALITY PEDIATRIC HOSPITAL AND POST-GRADUATE TEACHING INSTITUTE, SECTOR 30, NOIDA. 201303

### 12. Use of Biological / Hazardous materials

a) Hee of fetal tissue or abortus

(Tick appropriately or write NA if not applicable)

-		1		
L)nes	VOUL	research	invo	Ve.
Docs	your	rescuren	111 / 0	

a)	Use of	letal tissue of aboltus	res / INO
b)	Use of	organs or body fluids	Yes / No
c)	Use of	recombinant or gene therapy	Yes / No
	a.	If yes, has approval for use of rDNA products been obta	ined from Department of
		Biotechnology (DBT)	Yes / No
d)	Use of	pre-existing / stored / left over samples	Yes / No
e)	Collec	tion for banking or future research	Yes / No
f)	Use of	ionizing radiation / radioisotopes	Yes / No
	a.	If yes, have you obtained approval for use of radioactive	isotopes from Bhaba Atomic
		Research Centre (BARC)	Yes / No

### 13. Foreign collaboration

- a) Will any sample collected from the patient be sent abroad Yes / Noa. If yes, please provide justification and details (attach separately if needed)
  - i. Facility not available in India
  - ii. Facility not accessible

g) Use of infectious / bio-hazardous specimens

h) Ensure proper disposal of material

- iii. Facility is available but not being accessed
- iv. Others
- b) Does your proposal involve foreign collaboration

Yes / No

Vec / No

Yes / No Yes / No

a. If yes, have you obtained clearance from Health Ministry's Screening Committee (HMSC) for international collaboration

Yes / No



SUPER SPECIALITY PEDIATRIC HOSPITAL AND POST-GRADUATE TEACHING INSTITUTE, SECTOR 30, NOIDA. 201303

# 14. Consent

a)	Indicat	e the nature of consent being taken in your study					
	a.	Written	c.	A	udio-visual		
	b.	Oral	d.	N	ot applicable		
b)	Has a v	written consent form been included your submission				Yes / No	
c)	Does th	he consent form satisfy the following?					
	a.	Drafted in understandable language				Yes / No	
	b.	Include a statement that the study involves research				Yes / No	
	c.	Include details regarding the sponsor for the study				Yes / No	
	d.	Describe the purpose and procedures for the study				Yes / No	
	e.	Describe the risks and discomforts that may occur of	lue t	o pa	articipation	Yes / No	
	f.	Include the benefits of research and participation (d	irect	t/inc	lirect)	Yes / No	
	g.	Involve a statement regarding the compensation for	part	ticip	oation	Yes / No	
	h.	Involve statement regarding compensation for study	rela	ated	injury	Yes / No	
	i.	Present alternatives to participation				Yes / No	
	j.	Include details about confidentiality of records				Yes / No	
	k.	Include contact information of the investigators				Yes / No	
	1.	Include a statement indicating that the consent is vo	lunt	ary		Yes / No	
	m.	Inform patient about right to withdraw at any point	duri	ng t	he study	Yes / No	
	n.	Include details about consent for future use of biolo	gica	ıl ma	aterial	Yes / No	
	0.	Talk about benefits on future commercialization				Yes / No	
	p.	Describe about the disease condition and prevention	1			Yes / No	
d)	Who w	vill obtain consent					
	a.	Principal investigator					
	b.	Co-investigator					
	c.	Nurse					
	d.	d. Counsellor					
	e.	Research staff					
	f.	Any other					

# 15. Advertising

a) Will there be advertising for recruitment of subjects



SUPER SPECIALITY PEDIATRIC HOSPITAL AND POST-GRADUATE TEACHING INSTITUTE, SECTOR 30, NOIDA. 201303

	a.	If yes,	then please inclu	de a copy of the advertising	material		
		i.	Posters		iii.	Brochures	
		ii.	Fliers		iv.	Website	
		v.	Others				
16	. <u>Risks a</u>	and Ber	<u>nefits</u>				
a)	Is the r	isk invo	lved in the study	reasonable compared to the	anticipated b	enefits	Yes / No
b)	Is there	e possibi	ility of discomfor	t for the participants			Yes / No
	a.	Physic	al	None / Minimal / More	than minim	al / High	
	b.	Social		None / Minimal / More	than minim	al / High	
	c.	Psycho	ological	None / Minimal / More	than minim	al / High	
c)	Is there	e benefit	t to the participan	t			Yes / No
	a.	Direct			c. Benefi	t to the socie	ty
	b.	Indirec	et		d. Benefi	t to the body	of science
17	. Data N	<u> Monitor</u>	ring				
a)	Is there	e a data s	and safety monite	oring committee / board (DS)	MR\9		Yes / No
b)			for reporting adv	•	wib):		Yes / No
U)	a.	-	the reporting wil				1 05 / 110
	a.		onsor	Ethics committee	DS	SMB	
	b.	•	e a plan for interi		Do	DIVID	Yes / No
			-	age and maintenance of all tr	ial databasa		Yes / No
	C.		-	age and maintenance of all ti	iai uatabase		1 68 / INO
			Tor now long _				
18	. <u>Comp</u>	<u>ensatio</u>	n for participat	<u>:ion</u>			
a)	Is there	e compe	nsation for partic	ipation in the study?			Yes / No
	a.	If yes (	(please give detai	ils)			
		i.	Monetary				
		ii.	In kind				
b)	Is there	e compe	nsation for injury	7			Yes / No
	a.	If yes					
		i.	By sponsor		iii.	By insuran	ce company
		ii.	By investigator		iv.	By any oth	er
19	. <u>Confli</u>	ct of int	<u>terest</u>				
	-	ve any co /Non-fin		in the conduct of this study		Yes / N	lo



SUPER SPECIALITY PEDIATRIC HOSPITAL AND POST-GRADUATE TEACHING INSTITUTE, SECTOR 30, NOIDA. 201303

If yes, please give details (use separate sheets if necessary)

# 20. Checklistforattacheddocuments

Project proposal – 10 Copies	Yes	No	NA
Curriculum Vitae of Investigators	Yes	No	NA
Brief description of proposal	Yes	No	NA
Patient information sheet	Yes	No	NA
Informed Consent form	Yes	No	NA
Investigator's brochure for recruiting subjects	Yes	No	NA
Copy of advertisements/Information brochures	Yes	No	NA
Copy of clinical trial protocol and/or questionnaire	Yes	No	NA
Institutional Ethics Committee clearance	Yes	No	NA
Institutional Animal Ethics Committee clearance	Yes	No	NA
CPCSEA clearance, if any	Yes	No	NA
HMSC/DCGI/DBT/BARC clearance if obtained	Yes	No	NA

Place: Signature & Designation of PI/Co-PI/Collaborator Date:

The PI should sign on all the pages of the application